Contact the Editorial Desk

Editorial correspondence

LKN Peptide welcomes correspondence on the research record itself: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, sermorelin, or tesamorelin, a regulatory update that changes an approval or compounding status, or a study that should be added to the references page. This category of correction — one that improves the accuracy or currency of the digest — is the most useful message this desk receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference, ideally with a DOI or PubMed identifier, so a proposed change can be verified against its source before anything is updated.

Editorial mailbox: editors@lknpeptide.com

What this desk cannot do

As a literature digest rather than a clinical service, this desk cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate, source, or evaluate any supplier. Sermorelin, tesamorelin, and the CJC-1295/ipamorelin combination each carry different regulatory statuses — from an approved prescription indication to unregulated research-chemical status — and none of that status information is a substitute for consulting a licensed clinician. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.